Amgen (AMGN) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
Amgen (AMGN) has a market capitalization of approximately
Amgen's trailing twelve-month P/E ratio is 25.4x, with a price-to-book (P/B) of 21.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Amgen runs a net profit margin of 20.9%, a gross margin of 71.5%, and an operating margin of 31.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Amgen reported revenue of
Amgen offers a trailing dividend yield of about 2.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Amgen carries a debt-to-equity ratio of 6.24x and a current ratio of 1.26x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amgen (AMGN) the key facts are: market cap
Get Amgen's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.